Quantitative Systems Pharmacology and Physiologically Based Pharmacokinetics, Bristol Myers Squibb, Princeton, NJ, 08536, USA.
Department of Mathematics, Michigan State University, East Lansing, MI, 48824, USA.
J Pharmacokinet Pharmacodyn. 2022 Feb;49(1):39-50. doi: 10.1007/s10928-021-09785-6. Epub 2021 Oct 12.
Quantitative systems pharmacology (QSP) is an important approach in pharmaceutical research and development that facilitates in silico generation of quantitative mechanistic hypotheses and enables in silico trials. As demonstrated by applications from numerous industry groups and interest from regulatory authorities, QSP is becoming an increasingly critical component in clinical drug development. With rapidly evolving computational tools and methods, QSP modeling has achieved important progress in pharmaceutical research and development, including for heart failure (HF). However, various challenges exist in the QSP modeling and clinical characterization of HF. Machine/deep learning (ML/DL) methods have had success in a wide variety of fields and disciplines. They provide data-driven approaches in HF diagnosis and modeling, and offer a novel strategy to inform QSP model development and calibration. The combination of ML/DL and QSP modeling becomes an emergent direction in the understanding of HF and clinical development new therapies. In this work, we review the current status and achievement in QSP and ML/DL for HF, and discuss remaining challenges and future perspectives in the field.
定量系统药理学(QSP)是药物研发中的一种重要方法,它有助于通过计算机生成定量的机制假设,并实现计算机试验。众多行业团体的应用以及监管机构的关注表明,QSP 正在成为临床药物开发中越来越重要的组成部分。随着计算工具和方法的快速发展,QSP 模型在药物研发方面取得了重要进展,包括心力衰竭(HF)。然而,HF 的 QSP 建模和临床特征描述仍然存在各种挑战。机器学习/深度学习(ML/DL)方法在广泛的领域和学科中取得了成功。它们为 HF 的诊断和建模提供了数据驱动的方法,并为 QSP 模型开发和校准提供了新的策略。ML/DL 和 QSP 建模的结合成为理解 HF 和临床开发新疗法的一个新兴方向。在这项工作中,我们回顾了 HF 的 QSP 和 ML/DL 的现状和成就,并讨论了该领域中尚存的挑战和未来展望。